FI4294257T3 - Menetelmä osittaisen lipodystrofian diagnosoimiseksi ja hoitamiseksi - Google Patents

Menetelmä osittaisen lipodystrofian diagnosoimiseksi ja hoitamiseksi

Info

Publication number
FI4294257T3
FI4294257T3 FIEP22708698.0T FI22708698T FI4294257T3 FI 4294257 T3 FI4294257 T3 FI 4294257T3 FI 22708698 T FI22708698 T FI 22708698T FI 4294257 T3 FI4294257 T3 FI 4294257T3
Authority
FI
Finland
Prior art keywords
chain variable
seq
amino acid
acid sequence
set forth
Prior art date
Application number
FIEP22708698.0T
Other languages
English (en)
Finnish (fi)
Inventor
Wenjun Zheng
Charles Harris
Bret Musser
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Application granted granted Critical
Publication of FI4294257T3 publication Critical patent/FI4294257T3/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/48—Other medical applications
    • A61B5/4869—Determining body composition
    • A61B5/4872—Body fat
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/72—Signal processing specially adapted for physiological signals or for diagnostic purposes
    • A61B5/7271—Specific aspects of physiological measurement analysis
    • A61B5/7275—Determining trends in physiological measurement data; Predicting development of a medical condition based on physiological measurements, e.g. determining a risk factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
    • A61B6/48—Diagnostic techniques
    • A61B6/482—Diagnostic techniques involving multiple energy imaging
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
    • A61B6/50—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment specially adapted for specific body parts; specially adapted for specific clinical applications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
    • A61B6/52—Devices using data or image processing specially adapted for radiation diagnosis
    • A61B6/5211—Devices using data or image processing specially adapted for radiation diagnosis involving processing of medical diagnostic data
    • A61B6/5217—Devices using data or image processing specially adapted for radiation diagnosis involving processing of medical diagnostic data extracting a diagnostic or physiological parameter from medical diagnostic data
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G16B40/20—Supervised data analysis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Surgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Optics & Photonics (AREA)
  • Radiology & Medical Imaging (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Data Mining & Analysis (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Biotechnology (AREA)
  • Databases & Information Systems (AREA)
  • Epidemiology (AREA)
  • Theoretical Computer Science (AREA)
  • Evolutionary Biology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Artificial Intelligence (AREA)
  • Physiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dentistry (AREA)
  • Software Systems (AREA)
  • Bioethics (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Evolutionary Computation (AREA)
FIEP22708698.0T 2021-02-22 2022-02-22 Menetelmä osittaisen lipodystrofian diagnosoimiseksi ja hoitamiseksi FI4294257T3 (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163152100P 2021-02-22 2021-02-22
PCT/US2022/017222 WO2022178382A1 (en) 2021-02-22 2022-02-22 Method for diagnosing and treating partial lipodystrophy

Publications (1)

Publication Number Publication Date
FI4294257T3 true FI4294257T3 (fi) 2025-12-19

Family

ID=80683255

Family Applications (1)

Application Number Title Priority Date Filing Date
FIEP22708698.0T FI4294257T3 (fi) 2021-02-22 2022-02-22 Menetelmä osittaisen lipodystrofian diagnosoimiseksi ja hoitamiseksi

Country Status (14)

Country Link
US (1) US20240153638A1 (enExample)
EP (1) EP4294257B1 (enExample)
JP (1) JP2024512255A (enExample)
DK (1) DK4294257T3 (enExample)
ES (1) ES3055018T3 (enExample)
FI (1) FI4294257T3 (enExample)
HR (1) HRP20251599T1 (enExample)
LT (1) LT4294257T (enExample)
PL (1) PL4294257T3 (enExample)
PT (1) PT4294257T (enExample)
RS (1) RS67523B1 (enExample)
SI (1) SI4294257T1 (enExample)
SM (1) SMT202500444T1 (enExample)
WO (1) WO2022178382A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020150473A2 (en) 2019-01-18 2020-07-23 Dogma Therapeutics, Inc. Pcsk9 inhibitors and methods of use thereof
BR112021013924A2 (pt) 2019-01-18 2021-09-21 Astrazeneca Ab Inibidores de pcsk9 e métodos de uso do mesmo
US12303604B1 (en) 2024-10-16 2025-05-20 Currax Pharmaceuticals Llc Pharmaceutical formulations comprising naltrexone and/or bupropion

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI824372B (zh) 2015-10-12 2023-12-01 美商再生元醫藥公司 活化瘦素受體的抗原結合蛋白
SMT202500283T1 (it) * 2018-04-06 2025-09-12 Regeneron Pharma Un anticorpo agonista del recettore della leptina da utilizzare per aumentare la massa ossea in un soggetto affetto da disfunzione metabolica o ipoleptinemia

Also Published As

Publication number Publication date
PL4294257T3 (pl) 2026-02-09
ES3055018T3 (en) 2026-02-09
SMT202500444T1 (it) 2026-01-12
PT4294257T (pt) 2025-11-28
LT4294257T (lt) 2025-12-29
US20240153638A1 (en) 2024-05-09
HRP20251599T1 (hr) 2026-01-30
WO2022178382A1 (en) 2022-08-25
JP2024512255A (ja) 2024-03-19
RS67523B1 (sr) 2026-01-30
EP4294257B1 (en) 2025-11-05
DK4294257T3 (da) 2025-12-08
EP4294257A1 (en) 2023-12-27
SI4294257T1 (sl) 2026-01-30

Similar Documents

Publication Publication Date Title
Cornell A review of GLP‐1 receptor agonists in type 2 diabetes: a focus on the mechanism of action of once‐weekly agents
JP2024512255A5 (enExample)
JP6377348B2 (ja) ＴＧＦ−βアンタゴニストを使用する心筋梗塞の処置
FI3773713T3 (fi) Leptiinireseptorin agonistivasta-aine käytettäväksi luumassan lisäämiseen aineenvaihdunnan toimintahäiriöstä tai hypoleptinemiasta kärsivällä yksilöllä
JP2020500852A5 (enExample)
WO2003059372A2 (en) Combined use of a glp-1 compound and a modulator of diabetic late complications
JP2000514091A (ja) 心筋症の処置
JP2001523214A (ja) Ｐｄｇｆアンタゴニストおよびヘパリンを使用する内膜過形成を抑制するための組成物
US7951777B2 (en) Compositions and methods for treatment of cardiovascular disease
JP2021532057A5 (enExample)
AU2003223474A1 (en) Method for treating anxiety and mood disorders in older subjects
JPWO2004019928A1 (ja) 肝疾患治療剤
JP2021532176A5 (enExample)
EP2467152A1 (en) Use of nkg2d inhibitors for treating cardiovascular and metabolic diseases, such as type 2 diabetes
US8729020B2 (en) Methods for the treatment of aortic fibrosis with VIP fragments
CA2624648A1 (en) Methods of decreasing vascular calcification using il-1 inhibitors
EP2035037A2 (en) Methods, compositions, and kits for treating shiga toxin associated conditions
TW202317110A (zh) 用於治療肝臟疾病的聯合治療
US20070161551A1 (en) Methods and compositions for the treatment of lipodystrophy
Michie et al. Sepsis and tumor necrosis factor--bedfellows that cannot be ignored
EP4532551A1 (en) Methods and compositions for treatment of thyroid eye disease
CA2552404A1 (en) Methods and compositions for the treatment of lipodystrophy
CZ297743B6 (cs) Pouzití acetyl-L-karnitinu ve spojení s biotinem k lécbe pacientu s diabetem mellitus typu 2 rezistentním na inzulín
Pietroletti et al. Enteroglucagon and peptide YY response after construction of a pelvic reservoir in humans
CN1354676A (zh) 用于心血管疾病疗法的氨基四氢化萘衍生物